Suppr超能文献

耐万古霉素肠球菌——24名儿科肿瘤病房患者的定植情况

Vancomycin-resistant-enterococci--colonization of 24 patients on a pediatric oncology unit.

作者信息

Schuster F, Graubner U B, Schmid I, Weiss M, Belohradsky B H

机构信息

Department of Pediatric Hematology and Oncology, University of Munich.

出版信息

Klin Padiatr. 1998 Jul-Aug;210(4):261-3. doi: 10.1055/s-2008-1043889.

Abstract

BACKGROUND

Colonization with multidrug-resistant vancomycin-resistant-enterococci (VRE) could become a serious problem, since there is no proven therapy in case of an infection or in case of transfer of glycopeptid-resistance to other organisms.

PATIENTS

Description of 24 from 48 pediatric oncology patients with VRE-colonization.

METHODS

Stool samples were taken from all patients of our pediatric oncology unit from March 1996 until June 1997. Barrier isolation was introduced in May 1996, a prudent use of glycopeptid antibiotica in July 1996.

RESULTS

193 stool sample examinations demonstrated that 24 (50%) of the 48 patients were colonized with VRE. 11 (46%) of these 24 patients were VRE-carriers at the time of their first examination; 9 (37%) patients acquired VRE during their therapy and 4 (17%) patients had come from other hospitals and already were VRE-positive when they entered our unit. In March 1997, one year after the outbreak only four patients still were VRE-positive, in June 1997 all of them were VRE-negative. The average time of colonization was 12.5 weeks. 17 (70%) of the 24 colonized patients had received glycopeptide antibiotics, 16 of them within two months before the appearance of VRE in their stool. Five colonized patients died, four of them because of their oncological illness, one because of a sepsis without proof of VRE in his blood. In the end none of our patients suffered from a VRE-infection, and besides that, the transfer of glycopeptid-resistance to other organisms was not observed.

CONCLUSION

With barrier isolation and a very restrictive use of glycopeptid-antibiotica, colonization can be decreased and even stopped. Inspite of the high number of colonized patients no VRE-infectious disease occurred.

摘要

背景

多重耐药的耐万古霉素肠球菌(VRE)定植可能会成为一个严重问题,因为在发生感染或糖肽类耐药性转移至其他生物体时,尚无经证实有效的治疗方法。

患者

描述了48例儿科肿瘤患者中24例VRE定植情况。

方法

1996年3月至1997年6月期间,采集了我们儿科肿瘤病房所有患者的粪便样本。1996年5月引入屏障隔离,1996年7月谨慎使用糖肽类抗生素。

结果

193次粪便样本检查表明,48例患者中有24例(50%)被VRE定植。这24例患者中,11例(46%)在首次检查时即为VRE携带者;9例(37%)患者在治疗期间获得VRE,4例(17%)患者来自其他医院,入院时已为VRE阳性。1997年3月,即暴发一年后,仅有4例患者仍为VRE阳性,1997年6月时所有患者VRE均为阴性。平均定植时间为12.5周。24例定植患者中有17例(70%)接受过糖肽类抗生素治疗,其中16例在粪便中出现VRE前两个月内使用过。5例定植患者死亡,其中4例死于肿瘤疾病,1例死于败血症,其血液中未检测到VRE。最终,我们的患者均未发生VRE感染,此外,也未观察到糖肽类耐药性转移至其他生物体的情况。

结论

通过屏障隔离和严格限制使用糖肽类抗生素,可减少甚至阻止定植。尽管定植患者数量众多,但未发生VRE感染性疾病。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验